Display options
Cite
Swafford AA, Ard JD, Beavers DP, et al. Risedronate to Prevent Bone Loss After Sleeve Gastrectomy: Study Design and Feasibility Report of a Pilot Randomized Controlled Trial. JBMR Plus. 2020;4(10):e10407doi: 10.1002/jbm4.10407.
Swafford, A. A., Ard, J. D., Beavers, D. P., Gearren, P. C., Fernandez, A. Z., Ford, S. A., Greene, K. A., Kammire, D. E., Nesbit, B. A., Reed, K. K., Weaver, A. A., & Beavers, K. M. (2020). Risedronate to Prevent Bone Loss After Sleeve Gastrectomy: Study Design and Feasibility Report of a Pilot Randomized Controlled Trial. JBMR plus, 4(10), e10407. https://doi.org/10.1002/jbm4.10407
Swafford, Ashlyn A, et al. "Risedronate to Prevent Bone Loss After Sleeve Gastrectomy: Study Design and Feasibility Report of a Pilot Randomized Controlled Trial." JBMR plus vol. 4,10 (2020): e10407. doi: https://doi.org/10.1002/jbm4.10407
Swafford AA, Ard JD, Beavers DP, Gearren PC, Fernandez AZ, Ford SA, Greene KA, Kammire DE, Nesbit BA, Reed KK, Weaver AA, Beavers KM. Risedronate to Prevent Bone Loss After Sleeve Gastrectomy: Study Design and Feasibility Report of a Pilot Randomized Controlled Trial. JBMR Plus. 2020 Oct 02;4(10):e10407. doi: 10.1002/jbm4.10407. eCollection 2020 Oct. PMID: 33103032; PMCID: PMC7574708.
Copy Download .nbib Format: NLM
Share it on

JBMR Plus. 2020 Oct 02;4(10):e10407. doi: 10.1002/jbm4.10407. eCollection 2020 Oct.

Risedronate to Prevent Bone Loss After Sleeve Gastrectomy: Study Design and Feasibility Report of a Pilot Randomized Controlled Trial.

JBMR plus

Ashlyn A Swafford, Jamy D Ard, Daniel P Beavers, Peri C Gearren, Adolfo Z Fernandez, Sherri A Ford, Katelyn A Greene, Daniel E Kammire, Beverly A Nesbit, Kylie K Reed, Ashley A Weaver, Kristen M Beavers

Affiliations

  1. Deparment of Health and Exercise Science Wake Forest University Winston-Salem NC USA.
  2. Weight Management Center Wake Forest Baptist Medical Center Winston-Salem NC USA.
  3. Department of Biostatistics and Data Science Wake Forest School of Medicine Winston-Salem NC USA.
  4. Department of Biomedical Engineering Wake Forest School of Medicine Winston-Salem NC USA.

PMID: 33103032 PMCID: PMC7574708 DOI: 10.1002/jbm4.10407

Abstract

Mounting evidence implicates bariatric surgery as a cause of increased skeletal fragility and fracture risk. Bisphosphonate therapy reduces osteoporotic fracture risk and may be effective in minimizing bone loss associated with bariatric surgery. The main objective of this pilot randomized controlled trial (RCT; Clinical Trial No. NCT03411902) was to determine the feasibility of recruiting, treating, and following 24 older patients who had undergone sleeve gastrectomy in a 6 month RCT examining the efficacy of 150-mg once-monthly risedronate (versus placebo) in the prevention of surgical weight-loss-associated bone loss. Feasibility was defined as: (i) >30% recruitment yield, (ii) >80% retention, (iii) >80% pills taken, (iv) <20% adverse events (AEs), and (v) >80% participant satisfaction. Study recruitment occurred over 17 months. Seventy participants were referred, with 24 randomized (34% yield) to risedronate (

CLINICAL TRIAL REGISTRATION: http://clinicaltrials.gov/show/NCT03411902. Weight Loss With Risedronate for Bone Health. © 2020 The Authors.

© 2020 The Authors. JBMR Plus published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research.

Keywords: ANTIRESORPTIVES; BONE QUANTITATIVE COMPUTED TOMOGRAPHY; CLINICAL TRIALS; DXA; FRACTURE PREVENTION

References

  1. Obes Rev. 2018 May;19(5):728-736 - PubMed
  2. Surg Obes Relat Dis. 2020 Feb;16(2):175-247 - PubMed
  3. Bone. 2017 Nov;104:101-105 - PubMed
  4. Clin Interv Aging. 2008;3(2):227-32 - PubMed
  5. Int J Obes (Lond). 2017 Nov;41(11):1654-1661 - PubMed
  6. J Clin Endocrinol Metab. 2015 Apr;100(4):1452-9 - PubMed
  7. Obes Surg. 2016 Jan;26(1):91-7 - PubMed
  8. Gastroenterology. 2000 Sep;119(3):631-8 - PubMed
  9. J Bone Miner Res. 2018 Dec;33(12):2140-2149 - PubMed
  10. World Health Organ Tech Rep Ser. 1994;843:1-129 - PubMed
  11. Mayo Clin Proc. 2008 Sep;83(9):1032-45 - PubMed
  12. J Bone Miner Res. 2016 Mar;31(3):672-82 - PubMed
  13. J Bone Miner Res. 2014 Jul;29(7):1507-18 - PubMed
  14. J Clin Densitom. 2008 Oct-Dec;11(4):473-7 - PubMed
  15. Obes Surg. 2018 Sep;28(9):2968-2975 - PubMed
  16. Lancet Diabetes Endocrinol. 2014 Feb;2(2):165-74 - PubMed
  17. Surg Obes Relat Dis. 2019 Aug;15(8):1252-1260 - PubMed
  18. N Engl J Med. 2003 Apr 10;348(15):1503-4 - PubMed
  19. Obes Surg. 2020 Jan;30(1):77-86 - PubMed
  20. J Clin Endocrinol Metab. 2019 Oct 1;104(10):4639-4650 - PubMed
  21. J Osteoporos Phys Act. 2017;5(4): - PubMed
  22. Am J Prev Med. 2009 May;36(5):452-7 - PubMed
  23. Surg Endosc. 2018 Jun;32(6):2650-2655 - PubMed
  24. Endocr Rev. 2002 Aug;23(4):517-23 - PubMed
  25. Curr Med Res Opin. 2006 Dec;22(12):2383-91 - PubMed
  26. Obes Surg. 2017 Aug;27(8):2129-2137 - PubMed
  27. J Bone Miner Res. 2020 Aug;35(8):1415-1423 - PubMed
  28. BMC Med Res Methodol. 2017 Feb 20;17(1):30 - PubMed
  29. J Clin Endocrinol Metab. 2013 Feb;98(2):541-9 - PubMed
  30. Obes Surg. 2019 Feb;29(2):579-584 - PubMed
  31. Int J Surg. 2014;12(9):976-82 - PubMed
  32. Obes Surg. 2019 Apr;29(4):1327-1342 - PubMed
  33. Obes Surg. 2016 Jul;26(7):1414-21 - PubMed

Publication Types

Grant support